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Abstract: Glioblastoma multiforme (GBM) remains one of the most deadly cancers, with 
modest advances in overall survival despite significant improvements in imaging, surgery, and 
molecular genomic understanding. The highest-grade glioma, GBM is a primary brain cancer that 
is molecularly heterogeneous among patients and even within the same patient. Key hallmarks 
include glioma-cell invasion, angiogenesis, and therapeutic resistance. While once considered 
a major player in glioma invasion, members of the MMP family are also associated with other 
key pathological hallmarks of glioma. Investigations into understanding MMP function in 
GBM were slowed due to the failed MMP-inhibitor trials for GBM in the 2000s. In contrast, the 
field of MMPs in other brain pathologies has flourished in such areas as traumatic brain injury, 
multiple sclerosis, and stroke. In the past decade, the increase in publicly available data sets 
documenting patient-biopsy molecular information has empowered laboratory investigations 
into the spectrum of genomic, transcriptomic, and proteomic changes associated with glioma, 
including MMPs. In this review, we selected one of these data sets to illustrate a small sample 
of information that can be obtained from such analyses. Combined with recent reports on the 
use of MMP-cleavable peptides for imaging and the multifunctionality of MMPs, including 
intracellular nonproteolytic actions in various cell types, this paves the way for new avenues of 
MMP research. Understanding the function of MMPs in host–tumor interactions both spatially 
and temporally during tumor progression and in response to treatment will be crucial for the 
advancement of targeting specific MMPs in GBM. The opportunities to explore MMP regula-
tion, expression, and function further in GBM have never been so great with progress in modern 
bioinformatics and molecular techniques, and it is hoped that advancements will translate in 
some way to patients diagnosed with GBM.
Keywords: glioblastoma, matrix metalloproteinase, glioma, brain
Introduction
Although there are over 120 types of primary brain cancer, the most deadly and among 
the most common is glioblastoma multiforme (GBM).1 In 2016, the World Health Orga-
nization (WHO) classification of central nervous system (CNS) tumors was updated 
to incorporate recognized molecular indicators with the classical histopathological 
categories.1 By integrating molecular genetics with classical pathology, it is believed 
that this will help guide treatment. GBM (WHO grade IV astrocytoma) can emerge 
de novo or develop from a malignant progression of a lower-grade diffuse astrocytoma 
(WHO grade II) or anaplastic astrocytoma (WHO grade III). The progression of a lower 
grade to a high grade is associated with mutations in IDH1 and IDH2.2
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GBM produces heterogeneous tumors even within the 
same patient, with intratumoral heterogeneity presenting 
regional differences in critical drives of tumor growth and 
treatment response.3 Prevalent vascular disorganization, 
angiogenesis, and invasion are key features. Despite advances 
in conventional therapies over the past few decades, there is 
no cure.4 Initial treatment usually includes surgical resection 
of the tumor mass, followed by radiation and chemotherapy 
(temozolomide [Tmz]).5,6 In virtually all cases, the tumor 
recurs, usually near the margins of the previous resection, 
frequently in a form that is more resistant to subsequent 
therapies. Less than 4% of patients with GBM survive 5 
years following diagnosis.7
While considered a major contributor to glioma inva-
sion, members of the MMP family are also associated with 
other key pathological hallmarks of glioma. Recent reports 
on the multifunctionality of MMPs, including intracellular 
nonproteolytic actions in various cell types, are intriguing8,9 
and pave the way for new avenues of MMP research built 
upon an already solid foundation.10 This review provides an 
overview on the structure/function and regulation of MMPs, 
but will primarily focus on relating data on MMP gene 
expression obtained from publicly available data sets and our 
reverse-transcription quantitative polymerase chain reaction 
(RT-qPCR) data demonstrating unique glioma-expression 
patterns of MMPs to proteolytic and recently identified 
novel, nonproteolytic MMP functions. Although previous 
MMP-inhibitory trials were largely unsuccessful,11 these 
recently identified functions not only open up new research 
avenues but may also lead to the identification of potentially 
targetable MMPs for therapeutics.
Overview
The 23 MMPs (also known as matrixins) are part of a larger 
protease family, the metzincins, and include the astacins, 
adamlysins, pappalysins and bacterial serralysins,12 some 
which have been implicated in glioma.13–15 MMPs are zinc-
dependent, calcium-containing endopeptidases responsible for 
a wide range of biological processes, including angiogenesis, 
migration, growth, metabolism, and cell survival. Therefore, 
MMP activity must be tightly regulated at multiple levels:16 
transcriptionally by multiple factors and posttranscriptionally 
by microRNAs, compartmentalization of the inactive proen-
zyme (zymogen), zymogen activation, and subsequent inhibi-
tion of the activated enzymes by endogenous inhibitors.17–20
MMPs are multidomain endopeptidases translated 
as latent proenzyme or zymogens (proMMPs) with an 
 archetypal domain arrangement, including a secretion signal 
(removed upon entry into the endoplasmic reticulum) fol-
lowed by an inhibitory propeptide (Pro) domain, a catalytic 
(Cat) domain, a proline-rich linker (or “hinge” region), and 
a hemopexin-like (Hpx) domain (Figure 1A). This organi-
zation accurately describes approximately half the family 
members; the others either lack the Hpx domain or contain 
additional ancillary domains important for cellular local-
ization, substrate recognition, and/or inhibitor binding. An 
extensive account of the structure–function relationship in 
MMPs is beyond the scope of this review; therefore, only a 
brief synopsis is provided in the following section. Interested 
readers are directed to excellent accounts of MMP structure 
elsewhere.21,22
Importance of structure–function 
relationship
The hydrolytic apparatus of the ~170-residue Cat domain 
resides within a shallow crevice of what is otherwise a roughly 
spherical tertiary structure combining three α-helices (hA–
hC) and a five-stranded (sI–sV) mixed β-sheet ( Figure 1B). 
The second of these helices (ie, hB) provides the base of 
the active-site cleft, and together with the subsequent loop 
region (hB–hC) contains the characteristic Cat-domain motif 
HEXGHXXGXXH, which harbors the residues involved in 
substrate hydrolysis: the three histidine side chains chelate 
the active-site Zn2+ ion, which together with the invariant 
glutamate supercharges a bound water molecule to perform 
a nucleophilic attack on the carbonyl carbon of the substrate’s 
scissile peptide bond.
Although originally named for their breakdown of the 
extracellular matrix (ECM), MMPs are now known to 
hydrolyze multiple substrate families, including growth 
factors, cytokines, cell-surface receptors, and even intracel-
lular components.23–25 The precise shape and character of 
the active-site cleft (determined by the amino-acid residues 
that line it) largely dictate each MMP’s substrate preference; 
notable regions include the so-called wall-forming segment 
(strand sIV; Figure 1B) and subsequent S1’ specificity loop 
(hB–hC).22 However, additional regions, more distant from 
the active site and often in ancillary (noncatalytic) domains, 
provide additional determinants of substrate specificity.26,27 
These regions are termed “exosites”.28 For example, in MMP2 
and -9, three tandem fibronectin type 2 (F2) domains, each 
~60 residues, are inserted into the sV–hB loop within the Cat 
domain (Figure 1A). These F2 domains provide supplemen-
tary binding sites for their substrates.
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With the exception of MMPs 7, 23, and 26, the Cat 
domain is linked to an Hpx domain via a proline-rich linker 
10–70 amino acids in length (Figure 1A). The Hpx domain is 
a ~190 residue, four-bladed β-propeller with a bound Ca2+ ion 
along its axis. For many MMPs and their substrates, the pre-
cise role of the Hpx domain in hydrolysis has not been inves-
tigated comprehensively. However, for others, it is an exosite 
location, eg, the domain is required for the collagenolytic 
activity of MMP1, -2, -8, -9, -13, and -14.29 Although type 
I collagen may not be a relevant MMP substrate in glioma, 
this dependence illustrates the potential for the Hpx domain 
to direct proteolysis by the Cat domain. The Hpx domain can 
also influence nonproteolytic interactions of MMPs within 
the ECM. For example, the Hpx domain is known to medi-
ate the interactions of MMP1, -2, and -9 with heparin,30 the 
binding of MMP1 to the I-domain of integrin α
2
β
1
,31 and in 
MMP9 and -14 it is the site of enzyme dimerization.32 In 
place of an Hpx domain, MMP23 possesses cysteine-rich 
and immunoglobulin-like domains.33
The inactivating Pro domain, a cluster of three α-helices 
with connecting loops, docks into the Cat domain’s active-site 
cleft (Figure 1C), maintaining latency by chemically neutral-
izing the reactive Zn2+ ion with an invariant Cys residue and 
sterically restricting substrate access.21 Activation from this 
hydrolytically-inert, proMMP state to the mature, active 
enzyme requires disruption of this Cys–Zn interaction, a 
mechanism known as the “cysteine switch”.34 In those MMPs 
possessing a furin-recognition sequence in the Pro–Cat linker 
(Figure 1A), the zymogen is activated by this proprotein con-
vertase during transit through the Golgi.35 In the other proM-
MPs, activation typically occurs after secretion and involves 
removal of the entire Pro domain through serial proteolytic 
truncations. The initial trigger for this may itself be a proteo-
lytic event, such as cleavage of the flexible, protease-sensitive 
“bait region” within the Pro domain of many proMMPs. This 
may be elicited by an activated molecule of the same MMP 
(a process termed “autolysis”) by other MMPs or certain 
serine proteases, such as plasmin.36 Alternatively, the initial 
Figure 1 Domain organization in MMPs.
Notes: (A) Overall schematic. Numbers indicate in which MMP family members the various features occur. (B) Representation of the Cat domain from MMP1 depicting the 
secondary-structure elements within the molecular envelope, and (magnified) details of the catalytic cleft depicting the roles of the His and Glu residues in the characteristic 
HEXGHXXGXXH motif. (C) Crystal structure of human proMMP1211 showing the relative arrangement of the Pro, Cat, and Hpx domains. Bound calcium and zinc ions are 
shown as white and gray spheres, respectively. The dotted red line indicates the approximate location of the unstructured “bait region” within the Pro domain.
Abbreviations: S, secretion signal; Pro, propeptide; Cat, catalytic; H, hinge region; Hpx, hemopexin; F, furin-recognition sequence; L, linker; G, glycosylphosphatidylinositol 
anchor; TM, transmembrane; F2, fibronectin type II; CR, cysteine-rich; Cy, cytoplasmic; Zn, zinc.
A
B C
F   :11, 14–17, 21, 23–25, 28 L  G   : 17, 25absent: 7, 26
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: 14–16, 24L TM Cy: 23IgCRF2F2F22, 9 :TM23 :
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triggering event may be an allosteric structural change (eg, 
membrane-association-triggered activation of proMMP7)37 
or chemical oxidation of the Zn2+-chelating Cys thiol by 
reactive oxygen species.36
Six MMPs are localized to the cell surface: four are 
integral membrane-type enzymes (MMPs 14, 15, 16, and 
24) with a type I transmembrane helix C-terminal to the Hpx 
domain and two (MMPs 17 and 25) have a glycosylphosphati-
dylinositol (GPI) anchor toward the C-terminus.38 Each mem-
brane-type MMP has a furin recognition sequence (RX[R/K]
R) in the Pro–Cat linker (Figure 1A), and is thus activated 
by proprotein convertase during passage to the cell surface. 
Similarly, the secreted MMPs 11, 21, 23, and 28 can also be 
activated by furin.21,38 In the case of MMP23, the zymogen is 
anchored to the membrane by a type II transmembrane helix 
N-terminal to the Pro domain. It is simultaneously activated 
and shed from the membrane upon furin cleavage.33
Once activated, MMPs are susceptible to strong inhi-
bition by α
2
-macroglobulin and TIMPs, a family of four 
endogenous proteins, each of which is capable of forming 
a binary complex with an MMP Cat domain.39,40 In general, 
TIMPs show broad cross-reactivity with MMPs, but sensitiv-
ity varies for different MMP–TIMP pairings (eg, TIMP1 is 
only a weak inhibitor of MMPs 14, 16, 19, and 24). TIMPs 
are extensively disulfide-bonded and contain two domains 
with the N-terminal domain providing the inhibitory activ-
ity, the wedge-shaped structure of which docks into the 
active-site cleft, with the N-terminal Cys residue chelating 
the catalytic zinc.40 In addition to blocking MMP hydrolytic 
activity, TIMPs display other, noninhibitory roles.21,39 For 
example, TIMP2 recruits proMMP2 for activation at the cell 
surface by an MMP14 dimer and a ternary complex forms in 
which a TIMP2 molecule, already inhibiting one monomer 
of an MMP14 dimer via its inhibitory N-terminal domain, 
binds through its (noninhibitory) C-terminal domain to the 
proMMP2 Hpx domain, orienting the zymogen for proteoly-
sis of its Pro domain by the second (uninhibited) MMP14 
monomer.32 Intriguingly, chlorotoxin (a scorpion toxin that 
has anti-invasive effects on glioma cells) interacts specifically 
with MMP2, both reducing its cell-surface expression and 
inhibiting its hydrolytic activity.41
MMPs in gliomas: past and present
There is ample evidence suggesting a correlation between 
specific MMPs and glioma progression.42–47 Data from both 
in vitro and in vivo studies using glioma models point to a 
role of MMPs in glioma pathobiology. In addition, this field 
has gained insight from other neuropathology, including 
traumatic brain injury, stroke, neurodegenerative diseases, 
and immunorelated pathologies of the CNS, such as mul-
tiple sclerosis.48–52 While most of the published data focus 
on glioma-cell invasion, there is growing evidence of MMP 
involvement in other hallmarks of cancer, eg, angiogen-
esis.53–55 As in many fields of medical research, lessons were 
learned from failed clinical trials. Excitement over the ability 
to inhibit glioma invasion by targeting MMPs in patients with 
GBM was welcomed. Marimastat, a broad-spectrum MMP 
inhibitor developed in the late 1990s/early 2000s was the 
first orally bioavailable MMP inhibitor to reach clinical trials 
following in vitro and in vivo research showing high levels of 
efficacy in multiple cancer types.56,57 However, once clinical 
trials began, it became clear that one of the major adverse 
effects in humans was moderate–severe joint and muscle 
pain, which was present in up to 60% of patients. Unfortu-
nately, the impact on progression-free and overall survival 
was limited, and in some cases treatment with marimastat led 
to negative patient outcomes. Marimastat was tested alone 
and in conjunction with other chemotherapeutic agents and 
radiation, demonstrating benefit in only a few cases, but more 
often leading to severe musculoskeletal toxicity. It became 
apparent quite quickly from these trials that many MMPs 
have functions essential for normal physiological functions, 
and developing selective MMP inhibitors would be essential 
for effective therapeutic targeting of MMPs. In hindsight, the 
absence of selectivity and the importance of appropriately 
timing therapy in relation to tumor growth are only two 
hurdles of many that must be overcome. The heterogeneous 
cellular composition within GBM is a major barrier to suc-
cessful intervention, as is distinct host–tumor interactions 
that change and develop over time and in response to treat-
ment. The relatively recent revelation that certain MMPs 
have intracellular nonproteolytic functions contributes to 
this complexity.8,9,58 Until we learn more about the temporal 
and spatial expression and activity of MMPs in GBM and 
develop MMP-specific inhibitors, it will be difficult to foresee 
successful GBM treatment utilizing MMP-based therapies.
MMP gene expression in GBM
To provide some context for this review, we performed 
bioinformatic analyses using a publicly available data set 
– R2: Genomics Analysis and Visualization (http://r2.amc.
nl) – to assess MMP-mRNA expression. This is a valuable 
resource, and contains over 50,000 human samples from a 
wide range of tumors, tissues, and diseases, including GBM, 
many containing treatment and survival information. The 
French – 284 – MAS5.0 – u133p2 data set was  interrogated 
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to obtain relative MMP gene expression in GBM and deter-
mine the relationship of expression with Kaplan–Meier 
survival-probability estimates. This data set contains 276 
histologically confirmed samples: GBM; 159 astrocytomas, 
eight grade I, 13 grade II, and 16 grade III; eight normal brain; 
28 mixed oligoastrocytomas; and 52  oligodendrogliomas.59 
For our analyses, we first surveyed the relationship of MMP-
mRNA expression with the probability of overall survival 
across all the glioma types represented in this patient data 
set (Figure 2). Nine MMPs had low mRNA-expression 
levels in glioma that correlated with poor survival (MMPs 
3, 12, 13, 16, 20, 21, 24, 25, and 28; P<0.02), while eleven 
MMPs had high mRNA-expression levels that correlated 
with poor survival (MMPs 1, 2, 7, 8, 9, 10, 11, 14, 17, and 
23; P<0.02). When data were partitioned as GBM vs grade 
II and III and control tissue, MMP1, -2, -7, -9, -14, and -19 
mRNA levels were significantly higher in GBM. MMP1 was 
significantly higher in GBM compared to control and ana-
plastic astrocytoma (P=<0.0001). MMP2 was significantly 
higher in both anaplastic astrocytoma and GBM compared 
to control (P=0.0006 and 0.0001, respectively; Figure 3A). 
However in this data set, MMP2 levels did not associate 
with increasing grade and were not consistent with a recent 
report by Ramachandran et al in which more detailed analy-
sis using a different data set was conducted, demonstrating 
MMP2 expression increases with increasing grade.60 Based 
on previous reports, it was anticipated that MMP1, MMP2, 
and MMP9 mRNA levels would be high in GBM.53,61–65 Sur-
prisingly, MMP19 mRNA was significantly higher in GBM, 
not only compared to control (P<0.0001) but also relative to 
lower-grade gliomas (P<0.0006) (Figure 3A). Interestingly, 
only one MMP, MMP24, was significantly lower in GBM 
compared to controls and other gliomas (P<0.0001). When 
survival probability was assessed in just the GBM samples, 
high mRNA-expression levels of MMPs 1, 2, 7, 9, 12, and 19 
were associated with poor survival (Figure 3B), whereas low 
levels of MMP24 were associated with poor survival in this 
data set (Figure 3C). MMP24, identified by and characterized 
by Pei et al in 2000, is temporally and spatially regulated 
during neurodevelopment,66 associated with neurons,67 and 
reported to be associated with synaptic reorganization follow-
ing traumatic brain injury.51 This current analysis of MMP24 
expression in GBM appears to be in conflict with a previous 
study, where MMP24 was reported to be overexpressed in 
brain tumors.68 However, when GBM samples were examined, 
only two of seven demonstrated MMP24 transcripts. It is also 
not known if the MMP24 transcript variant described by Ross 
and Fillmore is associated with GBM.69 In this study, the 
authors report the upregulation of MMP24 in differentiated 
multipotent NT2 cells (a neurogenic in vitro model for dif-
ferentiation). Based on our improved knowledge of MMPs, 
it may not be surprising that not all MMPs will follow the 
same pattern in gliomas. In the context of the tumor micro-
environment, where there is multidirectional and dynamic 
communication between host cells (including neurons) and 
glioma cells, we would predict that neurally associated MMPs 
may have differential expression and functional patterns.70
The bioinformatic data obtained for MMPs 1, 2, 7, 9, 
19, and 24 are consistent with data obtained from RT-qPCR 
(Figure 4). mRNA-expression levels in control tissue (ie, 
non-pathological tissue obtained during surgical resection 
of epilepsy patients), grade III anaplastic astrocytoma, and 
GBM were assessed using custom-designed TaqMan low-
density arrays containing primer and probe sets for 384 
proteases. Transcript levels of MMPs 1, 2, 7, 9, 10, 11, 12, 
14, 19, and 21 were significantly increased in GBM relative 
to control. Notably, MMP19 was also increased in anaplastic 
astrocytoma relative to control, but decreased in grade IV 
GBM relative to grade III anaplastic gliomas.
Insofar as RNA levels are dependent on transcript sta-
bility and degradation by miRNAs, we surveyed in silico 
which miRNAs may be likely MMP-mRNA regulators. 
miRNA-expression signatures characterize and contribute 
to the phenotypic diversity of GBM subclasses through their 
ability to regulate developmental growth and differentiation. 
Furthermore, they have been identified as diagnostic and 
prognostic biomarkers for patient stratification, and may 
also serve as therapeutic targets and agents.71 We utilized 
the miRNA-target-prediction program TargetScan (http://
www.targetscan.org) to review the miRNA-target sites of 
these MMPs (Table 1). Not surprisingly, all but two MMPs 
(MMP12 and MMP23A/B) contained binding sites for 
at least one miRNA, but many of these sites were poorly 
conserved. More importantly, nine MMPs (MMPs 2, 3, 11, 
13, 14, 15, 16, 19, and 24) also demonstrated conserved 
miRNA-binding sites. Several of these sites have been previ-
ously described in GBM (miR587, -223, -377, -29c, -544, 
-136, -339, and -140).71–75 miR27b and miR29c have been 
experimentally validated to target their respective MMPs 
(MMP13 and MMP2) in other pathologies.76–86
Breaking out of the invasion box
While the majority of reports on MMP and GBM have 
focused on their role in glioma invasion, over the past few 
years it has become abundantly clear that MMPs are more 
than just “machetes” clearing ECM molecules out of the 
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Figure 2 Kaplan–Meier curves of overall-survival probability across all glioma-tumor types in French data set separated based on MMP gene expression.
Notes: The Kaplan Scan function of R2 was used to display Kaplan–Meier information with the cutoff modus set at “scan”. This function finds the best-possible curve based 
on log-rank test to find the most significant expression cutoff for survival.
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Figure 3 Gene-expression analysis of MMPs of 276 glioma samples of all histologies, with eight control samples.
Notes: Data set (tumor glioma – French – 284 – MAS5.0 – u133p2) retrieved from R2 Genomics Analysis and Visualization Platform (http://r2.amc.nl). (A). Data reported 
as mean ± SEM. P values: #<0.0001; ***0.0006; **0.0039. Two-way ANOVA was performed using GraphPad Prism. (B) Kaplan–Meier curves of overall-survival probability of 
156 GBM patients in French data set. MMPs significantly overexpressed in GBM patients compared to control, and patients had worse overall-survival probability. (C) MMP24 
was significantly underexpressed in GBM patients, and patients with lower expression had worse overall-survival probability.
Abbreviations: SEM, standard error of the mean; ANOVA, analysis of variance; GBM, glioblastoma multiforme.
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way for glioma cells to move.53 Their influences on cell 
growth, apoptosis, and inflammation are just a few of their 
biological roles that impact tumorigenicity. Elucidation of 
these mechanisms has not only generated intriguing results 
in this area but also opened new potential therapeutic avenues 
for GBM treatment.
Angiogenesis
In addition to being a highly invasive tumor, GBM is known 
to exhibit a high degree of vascularity. Indeed, one of the 
determining pathological hallmarks is extensive vascular 
hyperplasia, in addition to areas of necrosis and pseudopali-
sading zones demarcating areas of low oxygen. As oxygen 
is essential for the survival and proliferation of tumor cells, 
molecular cross talk between the tumor and the host microen-
vironment plays a crucial role in the activation of molecular 
pathways that affect endothelial cells and promote abnormal 
vessel formation.87,88 One of the key molecules involved in 
angiogenesis is VEGF, released by tumor cells and over-
expressed in most malignancies, including brain tumors.89 
Clinical trials using a humanized monoclonal antibody to 
VEGFA (Avastin [bevacizumab]), while revealing improve-
ment in progression-free survival, often fail to demonstrate 
improvement in overall survival.90 Reports from both human 
and animal studies support the mechanism of bevacizumab 
GBM vascular normalization).90,91 Even though bevacizumab 
shows improved progression-free survival, the tumor adapts 
and becomes more aggressive (invasive) and more resistant 
to treatment.92,93
Historically, MMPs have been linked to angiogenesis 
mostly by their ability to degrade the basal lamina (BL) 
components that support the blood–brain barrier and by their 
Figure 4 Quantitative reverse-transcription PCR.
Notes: PCR revealed significantly increased mRNA expression of MMPs 1, 2, 7, 9, 10, 11, 12, 14, 19, and 21 in GBM tumors relative to control tissue (ie, nonpathological 
tissue obtained during surgical resection in epilepsy patients). *P<0.05; **P<0.01; #P<0.001. mRNA-expression levels in control tissue (ie, nonpathological tissue obtained 
during surgical resection in epilepsy patients), grade III anaplastic astrocytoma, and GBM were assessed using custom-designed TaqMan low-density arrays containing primer 
and probe sets for 384 proteases, as previously described.195,196
Abbreviations: PCR, polymerase chain reaction; GBM, glioblastoma multiforme.
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regulation via cytokines and growth factors that play major 
roles in angiogenesis. The blood–brain barrier dynamically 
protects the brain, and is composed of what is called the 
“neurovascular unit”. For this review, we want to highlight 
the major cell types and unique BL ECM molecules. Brain 
endothelial cells are specialized and characterized by a com-
plex network of adhesion molecules, tight-junction proteins, 
and associated cytoplasmic proteins. Brain endothelial cells 
compose the capillary lumen and are surrounded by the BL 
and pericytes. Pericytes, critical in vascular homeostasis and 
stabilization, are typically embedded within the BL, which 
is composed of collagens I and IV, fibronectin, laminin, 
thrombospondin, and proteoglycans (agrin and perlecan).94–96
As with GBM being heterogeneous in nature, so are the 
vasculature structures generated to supply the tumor. There 
are at least five documented mechanisms of neovasculariza-
tion theorized in GBM pathobiology: vessel co-opting,97,98 
angiogenesis,99,100 vasculogenesis,101 vascular mimicry,102 and 
transdifferentiation of glioma cells to endothelial cells.103,104 
In an elegant (and highly recommended) review, Hardee and 
Zagzag105 described each of these processes and provided a 
review of published reports that support each mechanism 
in GBM. They also noted that these putative mechanisms 
to provide oxygen to the tumor are not always exclusive, 
but are molecularly linked to one another and overlap under 
certain situations. Rather than correlating specific MMPs 
with angiogenesis, it would be beneficial to interrogate the 
specific mechanistic roles of MMPs in each of these angio-
genic processes.
MMPs have been shown to have both proangiogenic 
and antiangiogenic roles in tumor angiogenesis106–108 and 
specifically in GBM.105 MMP2 and MMP9 play a critical 
role in the angiogenic switch when a tumor is initially vas-
cularized.109–111 Numerous in vitro and in vivo studies have 
shown the angiogenic implications of MMP2 and MMP9 in 
retinoblastoma, lung cancer, breast cancer, ovarian cancer, 
gastric cancer, and gliomas.112–121 Interestingly, studies have 
shown correlated expression of MMP2, MMP9, and MMP14 
with VEGF in GBM.122 Pullen et al showed the induction of 
angiogenesis in MMP1-overexpressing GBM cells in an in 
vivo model.53 MMP1 has also been shown to have a potential 
role in tumor vascularization through PAR1.13,53,123 MMP7 
induces endothelial cell proliferation by triggering MMP1 
and MMP2 endothelial cell expression.124,125
Certain MMPs can promote angiogenesis in different 
ways: pericyte detachment from sprouting vessels, while 
MMP9 plays an important role in recruiting pericytes;126 
induction of ECM-bound angiogenic growth factors, such 
as FGF, PDGF, VEGF, and TNFα;127,128 proteolytic cleavage 
of type IV collagen reveals increased cryptic α
v
β
3
 proangio-
genic integrin-binding sites and correlates with increased 
expression and activation of MMP2;129,130 and cleavage of 
the ectodomain of vascular–endothelial–cadherin cell–cell 
adhesions.108,131 MMPs also have antiangiogenic properties 
by cleaving plasma proteins and ECM components. MMP2, 
-7, -9, and -12 can inhibit angiogenesis by inducing plas-
minogen proteolytic cleavage and produce angiostatin.132–135 
MMP3, -9, -12, -13, and -20 can release endostatin, resulting 
in endothelial cell migration and apoptosis.135–137
In light of recent reports of “moonlighting” jobs, addi-
tional functions may exist for MMPs within mechanisms 
tumors use to obtain oxygen, as well as recruitment of other 
cell types, such as pericytes,138 neutrophils, bone-marrow 
derived endothelial cells, or macrophages and other myeloid 
cells. Historically, the investigation of MMPs in the CNS has 
been limited, due to the focus on documented ECM substrates 
and the lack of “appropriate” substrates for specific MMPs. 
As discussed by Jobin et al,8 experimental rigor and criteria 
are needed for studies designed to investigate these poten-
tially “novel” roles for MMPs.
Table 1 Conserved and poorly conserved sites at the 3′-end 
of matrix metalloproteinases, for miRNA binding predicted by 
TargetScan
Conserved sites Poorly conserved sites
MMP1 – miR587
MMP2 miR29c miR6811
MMP3 miR365b miR550
MMP7 – miR4764
MMP8 – miR6856
MMP9 – miR4530
MMP10 – miR6766
MMP11 miR4319 miR544b
MMP12 – –
MMP13 miR27b miR5692a
MMP14 miR4262 miR4466
MMP15 miR339 miR3663
MMP16 miR140 miR548
MMP17 – miR7111
MMP19 miR223 miR6890
MMP20 – miR1253
MMP21 – miR136
MMP23a/b – –
MMP24 miR3064 miR3976
MMP25 – miR6797
MMP26 – miR5585
MMP27 – miR377
MMP28 – miR4668
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Immune-system functions
It has long been understood that a variety of immune-system 
cells, beyond microglia, are effectors of neuroinflammation 
by trafficking into and out of brain parenchyma in response 
to neuroinflammatory insults, such as viral or bacterial 
infections, and this has been recently supported by the con-
firmation of brain lymphatics.139 For gliomas, involvement 
of extra-CNS cells is likely more acute, because of a com-
bination of signals produced by tumor cells and disruption 
of localized blood–brain barrier function.140 Here, we focus 
on the involvement of MMPs in glioma-mediated immune-
system responses. We begin with a discussion of specific 
cytokines, followed by a discussion of myeloid-lineage 
cells, specifically microglia/macrophages, mast cells, and 
neutrophils.
Cytokines
It is well known that GBM cells create an immunosuppressive 
microenvironment and utilize multiple methods to escape 
immunosurveillance. However, there is also evidence that 
GBM cells express antigens that are recognized by a patient’s 
immune system. Given the current clinical emphasis on 
immunotherapy for GBM and that GBM stem-like cells are 
prone to evading the immunoresponse, understanding the 
roles MMPs play in immunomodulation is essential. A great 
deal of the putative neuroimmune impacts of MMPs have 
been studied in the context of autoimmune disorders, such as 
multiple sclerosis (MS). MMP2 and -9 have been suggested 
as differential biomarkers for MS.141,142 Notably, MMP9 
expression is suppressed moderately by IFNβ143,144 and IgG, 
two commonly employed therapeutic approaches for MS.145 
Additionally, T-helper 1 (T
H
1) cells, which produce IFNγ, IL2, 
and TNFβ, which activate macrophages and are responsible 
for cell-mediated immunity, are the highest expressers of 
MMP2 and -9 among their CD4 cohorts. This could con-
tribute to greater motility and homing in an autoimmune 
setting.146 With the emergent interest in checkpoint-inhibitor 
therapeutics and more targeted therapies inherent to human 
leukocyte-antigen typing, it is worth examining the roles of 
MMPs in glioma-associated T cells, specifically CD8+, as 
well as other innate lymphoid-cell varieties.
With guidance from the MS field, IFNβ as a combina-
tion therapy for GBM has also been explored. The antitumor 
effect of Tmz on malignant glioma cells in vitro is improved 
with IFNβ.147 MMP2 induction by IFNβ treatment has also 
been reported in an in vivo mouse glioma model.148 However, 
unlike work done with respect to MS, there appears to be no 
effect of IFNβ treatment on MMP9 or TIMP1 expression, at 
least in cell lines.149 The latter study reported IL10 upregula-
tion as a potential mechanism for immunomodulation of the 
tumor microenvironment. This is especially interesting in 
light of recent studies from hypersensitivity research dem-
onstrating that IL10 has pro-T
H
2 inflammatory effects,150,151 
which are in contrast to IL10 being thought of as an immu-
nosuppressive cytokine. Could IL10 application be utilized 
to enhance antitumor immune-system responses, specifically 
T-cell and innate lymphoid-cell programming? In vitro, IL10 
has no significant effect on expression levels of MMP2, -3, 
-7, -9, or -12,152 yet paradoxically in the same study, it was 
noted that IL10 enhanced glioma cell-line invasion through 
mock basement membrane, an effect mitigated by marima-
stat. This begs the question as to the activation state of these 
MMPs and/or the expression of others. However, in the 
presence of IL10, activation of MMP2 or MMP9 was unaf-
fected.152 Recent evidence from clinical studies of IFNβ–Tmz 
combination therapy have demonstrated that this therapeutic 
approach has limited benefit.153 Furthermore, a small ret-
rospective analysis demonstrated median survival of 19.9 
months for IFNβ–Tmz combination therapy vs 12.7 months 
for Tmz alone.154 However, more recent molecular research 
suggests that IFNβ therapy enhances innate immunoeffectors 
in glioma stem-like cells,155 and thus additional research into 
IL10 and IFNβ therapy and MMP expression is warranted.
The effects of other cytokines on MMP expression in 
glioma cells have been investigated, including combinatorial 
responses to TNFα and IFNβ. Cheng et al reported that TNFα 
induced glioma-cell migration in vitro, and ascribed this to 
increased MMP3 expression.156 Transient MMP3 knockdown 
reduced invasion across mock basement membrane in the 
presence of TNFα. In addition, they showed that IFNβ sup-
pressed MMP3 transcription in a dose-dependent manner. 
The proposed mechanism involves inhibition of Ets1 and 
NFκB binding to DNA.156 However, it is unknown what NFκB 
subunits are affected, the role of TIMP3 (whose transcription 
was also suppressed), or whether IFNβ directly or indirectly 
inhibits glioma cell invasion. Conversely, TNFα and IFNβ 
both individually inhibit MMP2 expression and together 
impart an additive suppression of MMP2.157 Therefore, the 
effects of cytokines on MMP expression is MMP-specific.
IL6 and its major intracellular effector, STAT3, have 
been linked to enhanced MMP2 expression from glioma 
cell lines.158 A deeper study into the relationships among 
MMP2, IL6, and STAT3 revealed a novel role for MMP2 as a 
coeffector of the fibronectin receptor, α
5
β
1
 integrin, whereby 
MMP2 interacts directly with the receptor.159 Removal of 
MMP2 inhibited glioma-cell and xenograft proliferation, 
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inhibited production of multiple cytokines, including IL6, and 
inhibited STAT3 phosphorylation.159 IL6 promotes MMP14 
expression in glioma cell lines, and expressions of both IL6 
and MMP14 are increased in patient tumor samples.160 How-
ever, the localization of MMP14 is confounding, given other 
research161 showing that MMP14 imparts negative effects on 
glioma cells, yet it is a clear marker and effector of associ-
ated protumor microglia. Therefore, observations of MMP14 
on glioma cell lines in vitro likely do not replicate actual 
glioma cells in vivo. Nevertheless, the presence of MMP14 
in patient samples (likely in an immune-cell compartment) 
alongside IL6 is an impactive observation. Tocilizumab, an 
anti-IL6-receptor biologic, was US Food and Drug Admin-
istration-approved for moderate–severe rheumatoid arthritis 
this decade. The potential for off-label anti-IL6 therapies 
is becoming more attractive, given this cytokine’s role in 
cancer pathophysiology, which we submit might include 
MMP expression. Observations of IL6-receptor localiza-
tion on glioma-associated endothelia from patient samples, 
along with inhibition of glioma cell line proliferation by 
tocilizumab, have been reported.162 More mechanistic details 
utilizing xenograft models, which demonstrated hypoxia as a 
major inducer of IL6, showed that treatment with tocilizumab 
induced glioma cells to shift from an autophagic to apoptotic 
phenotype, thus increasing TMZ efficacy.163 Taken together, 
IL6 and MMP expressions in gliomas require further detailed 
study. While recent approaches to targeting IL6 itself have 
been scuttled (eg, sirukumab) due to adverse side effects, 
targeting the IL6 receptor has proven effective in other 
pathology, and other work using small-molecule inhibitors 
of the IL6–STAT3 axis show promise, such as work using 
stattic and cucurbitacin I.164
Glioma-associated microglia/macrophages
Most high-grade tumors, regardless of tissue origin, accu-
mulate mutations related to TGFβ overexpression, and 
gliomas are no exception to this. In turn TGFβ, along with 
other factors, such as GM-CSF, is a major recruitment 
and differentiation factor for immunosuppressive myeloid 
cells. Among those recently studied are glioma-associated 
microglia/macrophages (GAMs), a niche-specific nomen-
clature for tumor-associated macrophages (TAMs). Recent 
extensive reviews, including therapeutic approaches targeting 
microglia, are explained by  Roesch et al165 and Hambardzu-
myan et al.166 Recent work has sought to dissect further the 
pathological molecular mechanisms behind VEGF recep-
tor–TGFβ receptor complex activities,167 and indeed it has 
been shown that neuropilin 1 is a critical coreceptor in the 
induction of GAMs in a mouse model of glioma.168 Further-
more, GAMs are thought to contribute to the poor efficacy 
of some oncolytic viruses by sequestering and inhibiting the 
replication of the therapeutic virus.169 Specific to MMPs, the 
hypoxic environment characteristic of high-grade gliomas 
is known to induce MMP expression, and macrophages can 
independently induce MMP9 expression from glioma cells, 
with a slight additive effect in a hypoxic setting.170 Seminal 
work by Markovic et al demonstrated the key role of MMP14 
on GAMs, which in turn activate glioma-derived MMP2, 
thus enhancing the invasive capability of the tumor cells.161 
Using primary microglia from rats, Ellert-Miklaszewska et 
al171 broke ground in defining the transcriptomic network 
programmed into GAMs, which notably includes cementing 
MMP14 as a definitive marker of GAM activation. Further 
studies clearly defined the following: TLR2 (and to some 
extent TLRs 1 and 6) as mediators of the GAM MMP14 
conversion/phenotype,172 activation of TLR2 inducing these 
cells to express MMP9,173 and that the likely major stimulus 
for this TLR2-dependent activation was versican produced 
by glioma cells.174 Off-label use of atorvastatin has attracted 
attention in a variety of pathologies, including glioma, where 
it has been reported that it specifically suppresses MMP14 
on in vitro cultured GAM-like cells,175 and thus potentially 
inhibits glioma invasion by reducing MMP2 activation. 
Atorvastatin enhances Tmz-induced glioma-cell death in 
vitro and in xenograft models.176 Additionally, atorvastatin 
inhibits IL17R expression on glioma cell lines in vitro,177 
which is thought to be a keystone proglioma stem-cell 
effector.178 TGFβ (specifically TGFβ
1
) is also produced by 
GAMs/TAMs, and this source of cytokines has been shown 
to induce MMP9 expression and invasiveness of glioma 
stem cells in their local niche.179 Finally, investigators are 
cautioned to interpret semantics carefully when reading such 
reports as Bayat et al’s description of IL17RA inhibition as 
“anti-inflammatory”:177 proinflammatory is likely the desired 
effect in this specific setting, as it is immunosuppression and 
escape from immunosurveillance effected by GAMs/TAMs 
that supports progression of malignant cancers, including 
high-grade gliomas.
Mast cells
Packed with proteases including MMPs, mast cells are known 
to accumulate around tumor margins and within some tumor 
tissue, including high-grade gliomas. Surprisingly, the study 
of the roles of mast cells in CNS neoplasia is a neglected area. 
Typically, mast cells are considered only in the context of 
IgE-mediated hypersensitivity. However, in recent years these 
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myeloid granulocytes have gained attention in other areas, 
especially due to proven alternative, IgE-independent activa-
tion schemes, notably through IL33/ST2, and for their potent 
nociceptive effects on the somatosensory system (though 
mechanistic details are scant). A timely review of mast cells 
in neuroinflammation is explained by Skaper et al.180 Astro-
cytes are known to activate microglia through IL33,181 and 
furthermore there are reports linking IL33 induction with 
decreased survival time182 and IL33 stimulating expression 
of MMP2 and MMP9 from immortal cell cultures.183 Of 
note is that IL33 positively regulates mast-cell survival and 
inflammatory functions,184–186 and thus it will be important 
to investigate a potential pathological link between gliomas 
and mast cells via IL33 signaling. Mast cells decrease the 
efficacy of antiangiogenic therapies,187 which have histori-
cally been a focus of glioma-therapy research. Glioma cells 
also secrete factors that serve as signals for mast-cell homing 
in vivo, which include PAI1188 and CXCL12/SDF1.189 One 
in vitro study has reported detailed observations regarding 
mast cell–glioma cell coculture.190 Interestingly, glioma 
cell line-conditioned media alone were enough to stimulate 
IL6 secretion from mast cells, though the specific stimulus 
remains unknown. Paradoxically, the authors reported inhibi-
tion of glioma-cell STAT3 signaling despite enhanced IL6 
production, and termed these mast cells “tumor-educated”. 
Protease involvement was not assessed, and it will be impor-
tant to replicate this work with in vivo modeling.
Neutrophils
Neutrophils are the most abundant leukocytes in circulation 
and the namesake of MMP8 (neutrophil [polymorphonuclear] 
collagenase) – release of which can drive matrix-degradative 
pathology – such as seen in tuberculosis.191 Neutrophils 
invade gliomas, eg, a study of 105 patient samples reported 
that neutrophil infiltration was observed across all grades, 
and suggested that the degree of infiltration increased with 
grade, though without correlative statistical modeling.192 
Systemic neutrophilia with malignant disease is well known, 
and a recent meta-analysis reported that higher-than-normal 
circulating neutrophil:lymphocyte ratios were an indicator 
of poor prognosis for glioma patients.193 Treatment with 
bis-chloroethylnitrosourea or Tmz might induce prolonged 
posttreatment neutropenia in some glioma patients, with 
one case report of persistently dysfunctional neutrophils 
(specifically, deficient reactive oxygen species production) 
from patients treated with Tmz.194 An underlying mechanism 
linking Tmz to chronic neutropenia (and/or long-term neu-
trophil dysfunction) in a select patient subset has not been 
clearly defined. In a rat-flank glioma model, Graf et al195 
showed that IL6 could be important in the chemotaxis of 
antitumor neutrophils. Specifically, tumor-cell-derived IL6 
elicited neutrophil infiltration into the tumors and aspecific 
depletion of neutrophils in vivo was tumorigenic. Later work 
on mouse models of lung cancer showed distinct phenotypes 
of tumor-associated neutrophils, termed N
1
 and N
2
, that are 
tumoricidal and tumor-promoting, respectively, with the latter 
being TGFβ-dependent.196 A detailed review is provided by 
Uribe-Querol and Rosales.197 Therefore, neutrophilia asso-
ciated with high-grade neoplasia might be skewing toward 
an N
2
 phenotype. N
2
 neutrophils overlap functionally with 
but are likely a distinct population from polymorphonuclear 
myeloid-derived suppressor cells (MDSCs), which are also 
found in abundance in high-grade cancer cases.198 Harnessing 
the fact that regardless of phenotype, neutrophils potently 
invade brain tumors, Xue et al recently demonstrated proof 
of principle for using these cells to transport paclitaxel to 
brain tumors in an orthotopic mouse model noninvasively.199 
Phagocytic and degranulatory responses of neutrophils are 
long established, with the latter being a likely mechanism for 
neutrophil-mediated drug delivery. Furthermore, significant 
interest is garnered from the unique ability of neutrophils 
to eject sticky chromatin complexes as what are termed 
neutrophil extracellular traps (NETs). These were originally 
described as an aspecific antibacterial immunoresponse.200 
However, there is accumulating evidence that NETs may ful-
fill a protumor role and be activated more specifically through 
Fc receptors.197 In systemic lupus erythematosus, MMP9 
released with NETs activates MMP2.201 This report raises 
interest because of the predominance of gelatinases in past 
glioma studies. Additionally, it is notable that another recent 
report detailed a mechanism whereby MMP9-cleaved osteo-
pontin induced MDSC proliferation in a mouse lung cancer 
model. Altogether, there is need for much more research on 
the interplay of neutrophils with gliomas. Neutrophil-effector 
functions in the glioma setting hypothetically might include 
NET-associated MMP9 delivery, downstream activation of 
other pathways because of MMP9, induced release of MMP8, 
and expansion and recruitment of MDSCs, thus compounding 
issues of immunosuppression and tumor immunoevasion, and 
in turn MDSCs might support angiogenesis into tumors.202
Recent advances harnessing the 
immune system
Other recent emphases on the neuroimmunology of high-
grade glioma have obviously included development and trials 
with dendritic-cell and CAR T-cell therapies, but the research 
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here has not yet focused on potential roles of MMPs or much 
on proteases more generally (a review of the dendritic-cell 
field is provided by Reardon et al,203 and a timely perspective 
from leaders in the CAR T-cell field is provided by  Migliorini 
et al204). As mentioned already, GAMs might cordon off 
certain oncolytic therapies and MMPs are deeply involved 
in GAM activation and function. Safety trials of oncolytic 
therapies are just now being released, eg, with DNX2401,205 
and the PVSRIPO Phase I trial has recently concluded.206 
A recent major collaboration among several US labs also 
concluded that Zika virus has oncolytic potential, specifically 
targeting glioma stem cells.207 Clearly, the importance of 
diverse glioma-targeting immunotherapies has been demon-
strated, and our knowledge of the roles of metalloproteinases 
in these areas is constantly evolving.
Conclusion
While this review was not meant to cover all aspects of MMP 
function in glioma, our goal was to provide examples that 
would help free MMPs from the limitations they have been 
ascribed and to share our excitement for the future in terms 
of learning more about MMPs and better understanding 
the underlying pathobiology of GBM. The opportunities to 
explore MMP regulation, expression and function further in 
the CNS have never been so great. The public availability 
and size of patient-data platforms will only grow and become 
better. In addition to future exploration in terms of abnormal 
vessel formation, immunoresponse, and other host–tumor 
interactions, the use of MMPs for targeting and imaging 
of brain cancers is very encouraging.208,209 Other areas that 
lack information are MMP epigenetic and metabolic effector 
functions (including the epigenetic induction of MMPs). An 
almost uncharted territory in the brain for MMP enthusiasts 
are the unique mechanical properties of the brain parenchyma 
and the complicated changes that take place with the ECM 
during brain diseases.210 Much of what is known about MMP 
structure/function comes from studies in arthritis,10 and while 
Young’s modulus of brain tissue is quite different from bone, 
we believe there is a vast amount of information concerning 
mechanotransduction regulation of MMPs in gliomas. Little 
is known about the influence of fluid dynamics and sheer 
stress on temporal and spatial MMP functions in gliomas.
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